Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 24OTHER 9NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Gastrointestinal 2Dermatologic 2Plasma cell 1Lymphoid 1

Conditions

Thymoma 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Cisplatin 71Carboplatin 68Paclitaxel 57Radiotherapy 43Specimen Handling 37Gemcitabine 36Erlotinib Hydrochloride 32Etoposide 30Magnetic Resonance Spectroscopy 29Docetaxel 28Taxes 27Pemetrexed 23Platinum 20Vinorelbine 191,2-diaminocyclohexaneplatinum II citrate 19Bevacizumab 18Cyclophosphamide 16Biopsy 16Radiation 15pembrolizumab 14Immunoglobulin G 12Disulfides 12Topotecan 11Gefitinib 11durvalumab 9atezolizumab 9aldesleukin 9Nivolumab 9Irinotecan 9Bortezomib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × avelumab × Thoracic × Clear all
NCT06228066 2026-06-05

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
45 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT03076554 2026-05-29

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
56 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡